📣 VC round data is live. Check it out!
- Public Comps
- Supriya Lifescience
Supriya Lifescience Valuation Multiples
Discover revenue and EBITDA valuation multiples for Supriya Lifescience and similar public comparables like Phathom Pharmaceuticals, LB Pharmaceuticals, Sanofi India, Basilea Pharmaceutica and more.
Supriya Lifescience Overview
About Supriya Lifescience
Supriya Lifescience Ltd is a manufacturer of Active Pharmaceutical Ingredients. It is focused on diverse therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatic, and anti-allergic.
Founded
2008
HQ

Employees
515
Website
Financials (LTM)
EV
$765M
Valuation Multiples
Start free trialSupriya Lifescience Financials
Supriya Lifescience reported last 12-month revenue of $90M and EBITDA of $31M.
In the same LTM period, Supriya Lifescience generated $31M in EBITDA and $22M in net income.
Revenue (LTM)
Supriya Lifescience P&L
In the most recent fiscal year, Supriya Lifescience reported revenue of $87M and EBITDA of $32M.
Supriya Lifescience is profitable as of last fiscal year, with gross margin of 69%, EBITDA margin of 37%, and net margin of 25%.
Financial data powered by Morningstar, Inc.
Supriya Lifescience Stock Performance
Supriya Lifescience has current market cap of $772M, and enterprise value of $765M.
Market Cap Evolution
Supriya Lifescience's stock price is $9.60.
Supriya Lifescience share price decreased by 5.9% in the last 30 days, and increased by 25.3% in the last year.
Supriya Lifescience has an EPS (earnings per share) of $0.27.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $765M | $772M | -13.0% | -5.9% | 58.6% | 25.3% | $0.27 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSupriya Lifescience Valuation Multiples
Supriya Lifescience trades at 8.5x EV/Revenue multiple, and 24.3x EV/EBITDA.
EV / Revenue (LTM)
Supriya Lifescience Financial Valuation Multiples
As of June 4, 2026, Supriya Lifescience has market cap of $772M and EV of $765M.
Supriya Lifescience has a P/E ratio of 34.4x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Supriya Lifescience Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Supriya Lifescience Margins & Growth Rates
Supriya Lifescience grew revenue by 20% and EBITDA by 15% in the last fiscal year.
In the most recent fiscal year, Supriya Lifescience reported gross margin of 69%, EBITDA margin of 37%, and net margin of 25%.
Supriya Lifescience Margins
Supriya Lifescience Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Supriya Lifescience Operational KPIs
Supriya Lifescience's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Supriya Lifescience's Rule of 40 is 56% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Supriya Lifescience's Rule of X is 87% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Supriya Lifescience Competitors
Supriya Lifescience competitors include Phathom Pharmaceuticals, LB Pharmaceuticals, Sanofi India, Basilea Pharmaceutica, Oneness Biotech, Bright Minds Biosciences, ORIC Pharmaceuticals, Eton Pharmaceuticals, Kura Oncology and HK inno.N.
Most Supriya Lifescience public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 4.3x | 3.1x | (5.2x) | (9.9x) | |||
| - | - | (13.8x) | - | |||
| 3.7x | 3.6x | 13.7x | 13.2x | |||
| 2.3x | 2.2x | 10.6x | 9.7x | |||
| 147.9x | - | (26.8x) | - | |||
| - | - | (53.8x) | (12.1x) | |||
| - | - | (3.6x) | (3.4x) | |||
| 9.5x | 8.3x | 45.0x | 30.2x | |||
This data is available for Pro users. Sign up to see all Supriya Lifescience competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Supriya Lifescience
| When was Supriya Lifescience founded? | Supriya Lifescience was founded in 2008. |
| Where is Supriya Lifescience headquartered? | Supriya Lifescience is headquartered in India. |
| How many employees does Supriya Lifescience have? | As of today, Supriya Lifescience has over 515 employees. |
| Is Supriya Lifescience publicly listed? | Yes, Supriya Lifescience is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Supriya Lifescience? | Supriya Lifescience trades under SUPRIYA ticker. |
| When did Supriya Lifescience go public? | Supriya Lifescience went public in 2021. |
| Who are competitors of Supriya Lifescience? | Supriya Lifescience main competitors include Phathom Pharmaceuticals, LB Pharmaceuticals, Sanofi India, Basilea Pharmaceutica, Oneness Biotech, Bright Minds Biosciences, ORIC Pharmaceuticals, Eton Pharmaceuticals, Kura Oncology, HK inno.N. |
| What is the current market cap of Supriya Lifescience? | Supriya Lifescience's current market cap is $772M. |
| What is the current revenue of Supriya Lifescience? | Supriya Lifescience's last 12 months revenue is $90M. |
| What is the current revenue growth of Supriya Lifescience? | Supriya Lifescience revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Supriya Lifescience? | Current revenue multiple of Supriya Lifescience is 8.5x. |
| What is the current EBITDA of Supriya Lifescience? | Supriya Lifescience's last 12 months EBITDA is $31M. |
| What is Supriya Lifescience's EBITDA margin? | Supriya Lifescience's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of Supriya Lifescience? | Current EBITDA multiple of Supriya Lifescience is 24.3x. |
| How many companies Supriya Lifescience has acquired to date? | Supriya Lifescience hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Supriya Lifescience has invested to date? | Supriya Lifescience hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Supriya Lifescience
Lists including Supriya Lifescience
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.